Therefore, how to improve the percentage of ISH assay among traditionally HER2‐negative BC and how to identify the HER2‐low BC from the traditionally HER2‐negative BC with more easy‐to‐use methods would be a big challenge faced by several countries. This evidence concerns the gene ERBB2 and breast cancer.